NCT05795101 - TRUDI: TDXD+Durva in HER2+/Low IBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 4, 2023

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2032

Conditions

Invasive Breast CancerInflammatory Breast Cancer Stage IIIHER2-positive Breast CancerHER2 Low Breast AdenocarcinomaBreast Cancer

Interventions

DRUG

Trastuzumab deruxtecan

via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).

DRUG

Durvalumab

via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).

Trial Locations (3)

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston